Critical Contrast: BioScrip (BIOS) vs. The Competition
BioScrip (NASDAQ: BIOS) is one of 15 publicly-traded companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it compare to its peers? We will compare BioScrip to similar companies based on the strength of its dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Volatility & Risk
BioScrip has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, BioScrip’s peers have a beta of 1.58, suggesting that their average stock price is 58% more volatile than the S&P 500.
This table compares BioScrip and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares BioScrip and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioScrip||$935.59 million||-$41.50 million||-4.23|
|BioScrip Competitors||$1.06 billion||-$22.56 million||738.51|
BioScrip’s peers have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
84.4% of BioScrip shares are owned by institutional investors. Comparatively, 69.5% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by institutional investors. 0.8% of BioScrip shares are owned by insiders. Comparatively, 10.4% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent recommendations for BioScrip and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioScrip currently has a consensus target price of $3.75, suggesting a potential upside of 43.13%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 23.11%. Given BioScrip’s stronger consensus rating and higher probable upside, research analysts clearly believe BioScrip is more favorable than its peers.
BioScrip peers beat BioScrip on 8 of the 12 factors compared.
BioScrip Company Profile
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.